HUBBARD, Ohio, May 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc. a nano-biotechnology company is pleased to provide the following updates:
NanoLogix personnel will showcase company technology at booth 1304 at the ASM General Meeting and Exhibition in Boston, June 1-5 2008. The ASM meeting is the world's premier event for microbiology development. Representing NanoLogix will be Dr. Sergey Gazenko and CEO Bret Barnhizer. Exhibition information can be found at http://gm.asm.org/
At the ASM meeting NanoLogix will unveil ten products for use with their BNC and BNP technology for fast microorganism detection. This step is a milestone in company development. Director and company founder Dr. Robert A. Ollar, M.Sc., Ph.D. stated: "The sale of products developed by NanoLogix scientific staff marks an important stage in the evolution of the company. The firm is now putting its technologies into actual product configurations, and offering them for sale in the international market place where they will be utilized by the Global Scientific Community."
The company is also planning a new research and development facility in northeast Ohio. This facility will enable expanded R&D work on both Biohydrogen reactor development and BioNanoChannel (BNC) and BioNanoPore (BNP) technologies.
Hilda E. Diaz has joined NanoLogix in Cincinnati as assistant to Dr. Sergey Gazenko. Ms. Diaz holds an MS in Microbiology from Xavier University in Colombia, a BS in Bacteriology from Catholic University, and a BA in Business Administration. Ms. Diaz has extensive research and work experience in the field of microbiology. She was Professor in general microbiology, food microbiology and biotechnology at Catholic University in Colombia, and has extensive industrial experience in bacteriological testing. The company is pleased to have Ms. Diaz contributing to its efforts to further both Biohydrogen and BioNanoChannel technologies.
About NanoLogix, Inc.
NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at www.nanologixinc.com.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
CONTACT: Bret Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800,
Web site: http://www.nanologixinc.com/